CancerFree Biotech creates 3D tumor organoids from 20 mL of blood, using the organoids to test cancer therapeutics. Using our platform, which is called Ex Vivo Avatar (EVA), we culture the circulating tumor cells from patient blood samples to produce organoids that reflect each patient’s unique tumor composition. Our technology is used in precision medicine to produce patient treatment plans and in drug development research to test drug efficacy. As a precision medicine tool, we help doctors and patients create optimal treatment plans, limiting the risk of trying ineffective drugs. As a drug development tool, we accurately predict a developing drug’s clinical response, guiding pharmaceutical companies in making time- and cost-saving decisions.

To date, we have completed over 1500 patient cases across over 100 different solid tumor types. In Taiwan, we have partnerships with over 60 medical institutions across the country and 2 distributors. We are now looking to expanding beyond Taiwan, with Japan as a key target. As a result, we’ve entered and won several Japanese startup competitions, including first place at Kozarocks 2024 and finalist at SusHi Tech 2024. These prizes, which include office space and research institute introductions, will support our expansion into Japan.

www.cancerfree.io/en-us